Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin
We investigated whether measuring the excretion of each acute kidney injury (AKI) biomarker after cisplatin (CDDP) administration is useful for predicting AKI and evaluated the most appropriate AKI marker in patients treated with CDDP. We measured NAG, Kim-1, and NGAL in urinary samples of 40 cancer...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2017-09, Vol.37 (9), p.5235-5239 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5239 |
|---|---|
| container_issue | 9 |
| container_start_page | 5235 |
| container_title | Anticancer research |
| container_volume | 37 |
| creator | Maeda, Akimitsu Ando, Hitoshi Ura, Takashi Muro, Kei Aoki, Masahiro Saito, Ken Kondo, Eisaku Takahashi, Shinji Ito, Yuko Mizuno, Yasunari Fujimura, Akio |
| description | We investigated whether measuring the excretion of each acute kidney injury (AKI) biomarker after cisplatin (CDDP) administration is useful for predicting AKI and evaluated the most appropriate AKI marker in patients treated with CDDP.
We measured NAG, Kim-1, and NGAL in urinary samples of 40 cancer patients treated with chemotherapy on day 1 (before chemotherapy), day 2, and day 5 after treatment; serum creatinine (sCr) was compared on days 7 and 28 after CDDP administration vs. baseline.
NAG, Kim-1, and NGAL excretion (creatinine corrected) were not significantly elevated 5 days after receiving chemotherapy in the non-CDDP chemotherapy group. Conversely, all markers were significantly higher 5 days after receiving chemotherapy in the CDDP group when compared to baseline.
Urinary NAG, Kim-1, and NGAL can detect renal injury more sensitively than sCr. |
| doi_str_mv | 10.21873/anticanres.11947 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1935814255</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1935814255</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-94af9c8aacf5d627ec0a5f974a6e99e7644777ec968c38a5e9b396427ba214933</originalsourceid><addsrcrecordid>eNpFkMFKAzEURYMotlY_wI1k6WZqMkkmk6VWq0JBkXY9vKZvMDrN1CSD9O8d2qqrB5dzL7xDyCVn45yXWtyAT86CDxjHnBupj8iQa8MzrQQ7JkOWK5ZpxtSAnMX4wVhRmFKckkFelpoZZYbE3ru6xoDeYqTO00VwHsKWvqGHhk7BNV1AeufaNYRPDDtmAj0d6Cskhz5F-uxdctA0WzoPCAlX9NuldzpxcdP0jD8nJzU0ES8Od0QW04f55CmbvTw-T25nmRVSpsxIqI0tAWytVkWu0TJQtdESCjQGdSGl1n1qitKKEhSapTCFzPUSci6NECNyvd_dhParw5iqtYsWmwY8tl2suBGq5DJXqkf5HrWhjTFgXW2C61_cVpxVO7fVv9tq57bvXB3mu-UaV3-NX5niB1I8eLs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1935814255</pqid></control><display><type>article</type><title>Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Maeda, Akimitsu ; Ando, Hitoshi ; Ura, Takashi ; Muro, Kei ; Aoki, Masahiro ; Saito, Ken ; Kondo, Eisaku ; Takahashi, Shinji ; Ito, Yuko ; Mizuno, Yasunari ; Fujimura, Akio</creator><creatorcontrib>Maeda, Akimitsu ; Ando, Hitoshi ; Ura, Takashi ; Muro, Kei ; Aoki, Masahiro ; Saito, Ken ; Kondo, Eisaku ; Takahashi, Shinji ; Ito, Yuko ; Mizuno, Yasunari ; Fujimura, Akio</creatorcontrib><description>We investigated whether measuring the excretion of each acute kidney injury (AKI) biomarker after cisplatin (CDDP) administration is useful for predicting AKI and evaluated the most appropriate AKI marker in patients treated with CDDP.
We measured NAG, Kim-1, and NGAL in urinary samples of 40 cancer patients treated with chemotherapy on day 1 (before chemotherapy), day 2, and day 5 after treatment; serum creatinine (sCr) was compared on days 7 and 28 after CDDP administration vs. baseline.
NAG, Kim-1, and NGAL excretion (creatinine corrected) were not significantly elevated 5 days after receiving chemotherapy in the non-CDDP chemotherapy group. Conversely, all markers were significantly higher 5 days after receiving chemotherapy in the CDDP group when compared to baseline.
Urinary NAG, Kim-1, and NGAL can detect renal injury more sensitively than sCr.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>DOI: 10.21873/anticanres.11947</identifier><identifier>PMID: 28870959</identifier><language>eng</language><publisher>Greece</publisher><subject>Acute Kidney Injury - blood ; Acute Kidney Injury - chemically induced ; Analysis of Variance ; Biomarkers - blood ; Biomarkers - urine ; Cisplatin - administration & dosage ; Cisplatin - adverse effects ; Creatinine - blood ; Female ; Humans ; Male ; Middle Aged ; Neoplasms - blood ; Neoplasms - drug therapy ; Time Factors</subject><ispartof>Anticancer research, 2017-09, Vol.37 (9), p.5235-5239</ispartof><rights>Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-94af9c8aacf5d627ec0a5f974a6e99e7644777ec968c38a5e9b396427ba214933</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28870959$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maeda, Akimitsu</creatorcontrib><creatorcontrib>Ando, Hitoshi</creatorcontrib><creatorcontrib>Ura, Takashi</creatorcontrib><creatorcontrib>Muro, Kei</creatorcontrib><creatorcontrib>Aoki, Masahiro</creatorcontrib><creatorcontrib>Saito, Ken</creatorcontrib><creatorcontrib>Kondo, Eisaku</creatorcontrib><creatorcontrib>Takahashi, Shinji</creatorcontrib><creatorcontrib>Ito, Yuko</creatorcontrib><creatorcontrib>Mizuno, Yasunari</creatorcontrib><creatorcontrib>Fujimura, Akio</creatorcontrib><title>Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>We investigated whether measuring the excretion of each acute kidney injury (AKI) biomarker after cisplatin (CDDP) administration is useful for predicting AKI and evaluated the most appropriate AKI marker in patients treated with CDDP.
We measured NAG, Kim-1, and NGAL in urinary samples of 40 cancer patients treated with chemotherapy on day 1 (before chemotherapy), day 2, and day 5 after treatment; serum creatinine (sCr) was compared on days 7 and 28 after CDDP administration vs. baseline.
NAG, Kim-1, and NGAL excretion (creatinine corrected) were not significantly elevated 5 days after receiving chemotherapy in the non-CDDP chemotherapy group. Conversely, all markers were significantly higher 5 days after receiving chemotherapy in the CDDP group when compared to baseline.
Urinary NAG, Kim-1, and NGAL can detect renal injury more sensitively than sCr.</description><subject>Acute Kidney Injury - blood</subject><subject>Acute Kidney Injury - chemically induced</subject><subject>Analysis of Variance</subject><subject>Biomarkers - blood</subject><subject>Biomarkers - urine</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - adverse effects</subject><subject>Creatinine - blood</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasms - blood</subject><subject>Neoplasms - drug therapy</subject><subject>Time Factors</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMFKAzEURYMotlY_wI1k6WZqMkkmk6VWq0JBkXY9vKZvMDrN1CSD9O8d2qqrB5dzL7xDyCVn45yXWtyAT86CDxjHnBupj8iQa8MzrQQ7JkOWK5ZpxtSAnMX4wVhRmFKckkFelpoZZYbE3ru6xoDeYqTO00VwHsKWvqGHhk7BNV1AeufaNYRPDDtmAj0d6Cskhz5F-uxdctA0WzoPCAlX9NuldzpxcdP0jD8nJzU0ES8Od0QW04f55CmbvTw-T25nmRVSpsxIqI0tAWytVkWu0TJQtdESCjQGdSGl1n1qitKKEhSapTCFzPUSci6NECNyvd_dhParw5iqtYsWmwY8tl2suBGq5DJXqkf5HrWhjTFgXW2C61_cVpxVO7fVv9tq57bvXB3mu-UaV3-NX5niB1I8eLs</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>Maeda, Akimitsu</creator><creator>Ando, Hitoshi</creator><creator>Ura, Takashi</creator><creator>Muro, Kei</creator><creator>Aoki, Masahiro</creator><creator>Saito, Ken</creator><creator>Kondo, Eisaku</creator><creator>Takahashi, Shinji</creator><creator>Ito, Yuko</creator><creator>Mizuno, Yasunari</creator><creator>Fujimura, Akio</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170901</creationdate><title>Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin</title><author>Maeda, Akimitsu ; Ando, Hitoshi ; Ura, Takashi ; Muro, Kei ; Aoki, Masahiro ; Saito, Ken ; Kondo, Eisaku ; Takahashi, Shinji ; Ito, Yuko ; Mizuno, Yasunari ; Fujimura, Akio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-94af9c8aacf5d627ec0a5f974a6e99e7644777ec968c38a5e9b396427ba214933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acute Kidney Injury - blood</topic><topic>Acute Kidney Injury - chemically induced</topic><topic>Analysis of Variance</topic><topic>Biomarkers - blood</topic><topic>Biomarkers - urine</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - adverse effects</topic><topic>Creatinine - blood</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasms - blood</topic><topic>Neoplasms - drug therapy</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maeda, Akimitsu</creatorcontrib><creatorcontrib>Ando, Hitoshi</creatorcontrib><creatorcontrib>Ura, Takashi</creatorcontrib><creatorcontrib>Muro, Kei</creatorcontrib><creatorcontrib>Aoki, Masahiro</creatorcontrib><creatorcontrib>Saito, Ken</creatorcontrib><creatorcontrib>Kondo, Eisaku</creatorcontrib><creatorcontrib>Takahashi, Shinji</creatorcontrib><creatorcontrib>Ito, Yuko</creatorcontrib><creatorcontrib>Mizuno, Yasunari</creatorcontrib><creatorcontrib>Fujimura, Akio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maeda, Akimitsu</au><au>Ando, Hitoshi</au><au>Ura, Takashi</au><au>Muro, Kei</au><au>Aoki, Masahiro</au><au>Saito, Ken</au><au>Kondo, Eisaku</au><au>Takahashi, Shinji</au><au>Ito, Yuko</au><au>Mizuno, Yasunari</au><au>Fujimura, Akio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2017-09-01</date><risdate>2017</risdate><volume>37</volume><issue>9</issue><spage>5235</spage><epage>5239</epage><pages>5235-5239</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>We investigated whether measuring the excretion of each acute kidney injury (AKI) biomarker after cisplatin (CDDP) administration is useful for predicting AKI and evaluated the most appropriate AKI marker in patients treated with CDDP.
We measured NAG, Kim-1, and NGAL in urinary samples of 40 cancer patients treated with chemotherapy on day 1 (before chemotherapy), day 2, and day 5 after treatment; serum creatinine (sCr) was compared on days 7 and 28 after CDDP administration vs. baseline.
NAG, Kim-1, and NGAL excretion (creatinine corrected) were not significantly elevated 5 days after receiving chemotherapy in the non-CDDP chemotherapy group. Conversely, all markers were significantly higher 5 days after receiving chemotherapy in the CDDP group when compared to baseline.
Urinary NAG, Kim-1, and NGAL can detect renal injury more sensitively than sCr.</abstract><cop>Greece</cop><pmid>28870959</pmid><doi>10.21873/anticanres.11947</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2017-09, Vol.37 (9), p.5235-5239 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1935814255 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Acute Kidney Injury - blood Acute Kidney Injury - chemically induced Analysis of Variance Biomarkers - blood Biomarkers - urine Cisplatin - administration & dosage Cisplatin - adverse effects Creatinine - blood Female Humans Male Middle Aged Neoplasms - blood Neoplasms - drug therapy Time Factors |
| title | Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T17%3A05%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differences%20in%20Urinary%20Renal%20Failure%20Biomarkers%20in%20Cancer%20Patients%20Initially%20Treated%20with%20Cisplatin&rft.jtitle=Anticancer%20research&rft.au=Maeda,%20Akimitsu&rft.date=2017-09-01&rft.volume=37&rft.issue=9&rft.spage=5235&rft.epage=5239&rft.pages=5235-5239&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/10.21873/anticanres.11947&rft_dat=%3Cproquest_cross%3E1935814255%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1935814255&rft_id=info:pmid/28870959&rfr_iscdi=true |